Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 503-507

  Riedemann, Niels C ^a   Neff, Thomas A ^a   Guo, Ren Feng ^a   Bernacki, Kurt D ^a   Laudes, Ines J ^a   Sarma, J Vidya ^a   Lambris, John D ^b   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; IODINE 125; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; HEART; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SURVIVAL;

EID: 0037218519     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.503     Document Type: Article

References (40)

1. Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73.
2. Akira, S., T. Taga, and T. Kishimoto. 1993. Interleukin-6 in biology and medicine. Adv. Immunol. 54:1.
3. Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFN-β2) receptor. Science 241:825.
4. Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573.
5. Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, and T. Kishimoto. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149.
6. Geiger, T., T. Andus, J. Klapproth, T. Hirano, T. Kishimoto, and P. C. Heinrich. 1988. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur. J. Immunol. 18:717.
7. Gauldie, J., C. Richards, D. Harnish, P. Lansdorp, and H. Baumann. 1987. Interferon-β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84:7251.
8. van der Poll, T., M. Levi, C. E. Hack, H. ten Cate, S. J. van Deventer, A. J. Eerenberg, E. R. de Groot, J. Jansen, H. Gallati, H. R. Buller, et al. 1994. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179:1253.
9. Shalaby, M. R., A. Waage, L. Aarden, and T. Espevik. 1989. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin. Immunol. Immunopathol. 53:488.
10. Sheron, N., J. N. Lau, J. Hofmann, R. Williams, and G. J. Alexander. 1990. Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans. Clin. Exp. Immunol. 82:427.
11. Hack, C. E., E. R. De Groot, R. J. Felt-Bersma, J. H. Nuijens, R. J. Strack Van Schijndel, A. J. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704.
12. Helfgott, D. C., S. B. Tatter, U. Santhanam, R. H. Clarick, N. Bhardwaj, L. T. May, and P. B. Sehgal. 1989. Multiple forms of IFN-β2/IL-6 in serum and body fluids during acute bacterial infection. J. Immunol. 142:948.
13. Waage, A., P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik. 1989. The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169:333.
14. Calandra, T., J. Gerain, D. Heumann, J. D. Baumgartner, and M. P. Glauser. 1991. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines: The Swiss-Dutch J5 Immunoglobulin Study Group. Am. J. Med. 91:23.
15. Casey, L. C., R. A. Balk, and R. C. Bone. 1993. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119:771.
16. Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215:356.
17. Gardlund, B., J. Sjolin, A. Nilsson, M. Roll, C. J. Wickerts, and B. Wretlind. 1995. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J. Infect. Dis. 172:296.
18. Preiser, J. C., D. Schmartz, P. Van der Linden, J. Content, P. Vanden Bussche, W. Buurman, W. Sebald, E. Dupont, M. R. Pinsky, and J. L. Vincent. 1991. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 3:1.
19. Starnes, H. F., Jr., M. K. Pearce, A. Tewari, J. H. Yim, J. C. Zou, and J. S. Abrams. 1990. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol. 145:4185.
20. Smedegard, G., L. X. Cui, and T. E. Hugli. 1989. Endotoxin-induced shock in the rat: A role for C5a. Am. J. Pathol. 135:489.
21. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5:788.
22. Huber-Lang, M., V. J. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, et al. 2001. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166:1193.
23. Huber-Lang, M. S., J. V. Sarma, S. R. McGuire, K. T. Lu, R. F. Guo, V. A. Padgaonkar, E. M. Younkin, I. J. Laudes, N. C. Riedemann, J. G. Younger, and P. A. Ward. 2001. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 15:568.
24. Guo, R. F., M. Huber-Lang, X. Wang, V. Sarma, V. A. Padgaonkar, R. A. Craig, N. C. Riedemann, S. D. McClintock, T. Hlaing, M. M. Shi, and P. A. Ward. 2000. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 106:1271.
25. Gerard, N. P., M. K. Hodges, J. M. Drazen, P. F. Weller, and C. Gerard. 1989. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J. Biol. Chem. 264:1760.
26. Gerard, N. P., and C. Gerard. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature 349:614.
27. Riedemann, N. C., R. F. Guo, T. A. Neff, I. J. Laudes, K. A. Keller, J. V. Sarma, M. M. Markiewski, D. Mastellos, C. W. Strey, C. L. Pierson, et al. 2002. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110:101.
28. Schieferdecker, H. L., G. Schlaf, M. Koleva, O. Gotze, and K. Jungermann. 2000. Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J. Immunol. 164:5453.
29. Riedemann, N. C., R. F. Guo, I. J. Laudes, K. Keller, V. J. Sarma, V. Padgaonkar, F. S. Zetoune, and P. A. Ward. 2002. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16:887.
30. Riedemann, N. C., R. F. Guo, V. J. Sarma, I. J. Laudes, M. Huber-Lang, R. L. Warner, E. A. Albrecht, C. L. Speyer, and P. A. Ward. 2002. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168:1919.
31. Becherer, J. D., and J. D. Lambris. 1988. Identification of the C3b receptor-binding domain in third component of complement. J. Biol. Chem. 263:14586.
32. Bennett, G. L., and R. Horuk. 1997. Iodination of chemokines for use in receptor binding analysis. Methods Enzymol. 288:134.
33. Eskandari, M. K., G. Bolgos, C. Miller, D. T. Nguyen, L. E. DeForge, and D. G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724.
34. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110.
35. Libert, C., A. Vink, P. Coulie, P. Brouckaert, B. Everaerdt, J. Van Snick, and W. Fiers. 1992. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur. J. Immunol. 22:2625.
36. Heremans, H., C. Dillen, W. Put, J. Van Damme, and A. Billiau. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22:2395.
37. Gennari, R., and J. W. Alexander. 1995. Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit. Care Med. 23:1945.
38. Remick, D., P. Manohar, G. Bolgos, J. Rodriguez, L. Moldawer, and G. Wollenberg. 1995. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4:89.
39. Leon, L. R., A. A. White, and M. J. Kluger. 1998. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 275:R269.
40. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339.